The six-minute walk test in patients with pulmonary sarcoidosis

Annals of Thoracic Medicine

Volumn 4, Issue 2, 2009, Pages 60-64

  Alhamad, Esam H ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

6 min walk test; Functional status; Pulmonary sarcoidosis

Indexed keywords

AZATHIOPRINE; METHOTREXATE; PREDNISONE;

ADULT; ARTERIAL GAS; ARTICLE; BORG DYSPNEA SCORE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DIAGNOSTIC TEST; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL STATUS; HUMAN; MALE; OXYGEN SATURATION; PARAMETER; SARCOIDOSIS; SCORING SYSTEM; SEX DIFFERENCE; SIX MINUTE WALK TEST; SPIROMETRY; VITAL CAPACITY; WALKING;

EID: 66749100692     PISSN: 18171737     EISSN: 19983557     Source Type: Journal    
DOI: 10.4103/1817-1737.49414     Document Type: Article

References (44)

1. Silverstein A, Siltzbach LE. Muscle involvement in sarcoidosis: Asymptomatic, myositis, and myopathy. Arch Neurol. 1969; 21:235-241.
2. Flaherty KR, Andrei AC, Murray S, Fraley C, Colby TV, Travis WD, et al. Idiopathic pulmonary fibrosis: Prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 2006;174:803-9.
3. Sciurba F, Criner GJ, Lee SM, Mohsenifar Z, Shade D, Slivka W. Six-minute walk distance in chronic obstructive pulmonary disease: Reproducibility and effect of walking course layout and length. Am J Respir Crit Care Med 2003;167:1522-7.
4. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-92.
5. Alameri HF, Sanai FM, Al Dukhayil M, Azzam NA, Al-Swat KA, Hersi AS, et al. Six minute walk test to assess functional capacity in chronic liver disease patients. World J Gastroenterol 2007;13: 3996-4001.
6. Savd S, Inal-Ince D, Arikan H, Guclu-Gunduz A, Cetisli-Korkmaz N, Armutlu K, et al. Six-minute walk distance as a measure of functional exercise capacity in multiple sclerosis. Disabil Rehabil 2005;27:1365-71.
7. Roul G, Germain P, Bareiss P. Does the 6-minute walk test predict the prognosis in patients with NYHA class II or III chronic heart failure? Am Heart J 1998;136:449-57.
8. American Thoracic Society. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7.
9. Kabitz HJ, Lang F, Walterspacher S, Sorichter S, Muller-Quernheim J, Windisch W. Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis. Chest 2006;130: 1496-502.
10. Arcasoy SM, Christie JD, Pochettino A, Rosengard BR, Blumenthal NP, Bavaria JE, et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest 2001;120:873-80.
11. Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007;132:207-13.
12. Statement on Sarcoidosis. Joint Statement Of The American Thoracic Society (ATS), The European Respiratory Society (ERS) And The World Association Of Sarcoidosis And Other Granulomatous Disorders (WASOG) Adopted By The ATS Board Of Directors And By The ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160:736-55.
13. Standardization of Spirometry, 1994 update. American Thoracic Society. Am J Respir Crit Care Med 1995;152:1107-36.
14. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer-factor)-recommendations for a standard technique: 1995 update. Am Rev Respir Crit Care Med 1993;152:2185-98.
15. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7.
16. Borg G. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377-81.
17. Pietinalho A, Ohmichi M, Hiraga Y, Löfroos AB, Selroos O. The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan: A comparative analysis of 571 Finnish and 686 Japanese patients. Sarcoidosis Vase Diffuse Lung Dis 1996;13:159-66.
18. Baughman RP, Iannuzzi MC, Lower EE, Moller DR, Balkissoon RC, Winget DB, et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002;19:198-204.
19. Khan J, Døssing M, von Sinner WN, Bazarbashi M, Curley W. Sarcoidosis in native Saudis. Sarcoidosis 1993;10:50-5.
20. Samman Y, Ibrahim M, Wali S. Sarcoidosis in the western region of Saudi Arabia. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:215-8.
21. Behbehani N, Jay Krishnan B, Khadadah M, Hawa H, Farah Y. Clinical presentation of sarcoidosis in a mixed population in the middle east. Respir Med 2007;101:2284-8.
22. Wirnsberger RM, de Vries J, Wouters EF, Drent M. Clinical presentation of sarcoidosis in The Netherlands an epidemiological study. Neth J Med 1998;53:53-60.
23. Mayock Rl, Bertrand P, Morrison CE, Scott JH. Manifestations of sarcoidosis: Analysis of 145 patients, with a review of nine series selected from the literature. Am J Med 1963;35:67-89.
24. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164:1885-9.
25. Harrison BD, Shaylor JM, Stokes TC, Wilkes AR. Airflow limitation in sarcoidosis: A study of pulmonary function in 107 patients with newly diagnosed disease. Respir Med 1991;85:59-64.
26. Sharma OP, Johnson R. Airway obstruction in sarcoidosis: A study of 123 nonsmoking black American patients with sarcoidosis. Chest 1988;94:343-6.
27. Medinger AE, Khouri S, Rohatgi PK. Sarcoidosis: The value of exercise testing. Chest 2001;120:93-101.
28. Delobbe A, Perrault H, Maitre J, Robin S, Hossein-Foucher C, Wallaert B, et al. Impaired exercise response in sarcoid patients with normal pulmonary function. Sarcoidosis Vase Diffuse Lung Dis 2002;19:148-53.
29. Miller A, Brown LK, Sloane MF, Bhuptani A, Teirstein AS. Cardiorespiratory responses to incremental exercise in sarcoidosis patients with normal spirometry. Chest 1995;107:323-9.
30. Sietsema KE, Kraft M, Ginzton L, Sharma OP. Abnormal oxygen uptake responses to exercise in patients with mild pulmonary sarcoidosis. Chest 1992;102:838-45.
31. Spruit MA, Thomeer MJ, Gosselink R, Troosters T, Kasran A, Debrock AJ, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005;60:32-8.
32. Chetta A, Aiello M, Foresi A, Marangio E, D'Ippolito R, Castagnaro A, et al. Relationship between outcome measures of six-minute walk test and baseline lung function in patients with interstitial lung disease. Sarcoidosis Vase Diffuse Lung Dis 2001;18:170-5.
33. Paramathayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: A systemic review. JAMA 2002;287:1301-7.
34. Drent M, Wirnsberger RM, de Vries J, van Dieijen-Visser MP, Wouters EF, Schols AM. Association of fatigue with an acute phase response in sarcoidosis. Eur Respir J 1999;13:718-22.
35. Drent M, Wirnsberger RM, Breteler MH, Kock LM, de Vries J, Wouters EF. Quality of life and depressive symptoms in patients suffering from sarcoidosis. Sarcoidosis Vase Diffuse Lung Dis 1998;15:59-66.
36. Ziegenhagen MW, Müller-Quernheim J. The cytokine network in sarcoidosis and its clinical relevance. J Intern Med 2003;253:18-30.
37. Ziegenhagen MW, Fitschen J, Martinet N, Schlaak M, Muller-Quernheim J. Serum level of soluble tumour necrosis factor receptor II (75 kDa) indicates inflammatory activity of sarcoidosis. J Intern Med 2000;248:33-41.
38. Kadikar A, Maurer J, Kesten S. The six-minute walk test: A guide to assessment for lung transplantation. J Heart Lung Transplant 1997;16:313-9.
39. Poh H, Eastwood PR, Cecins NM, Ho KT, Jenkins SC. Six-minute walk distance in healthy Singaporean adults cannot be predicted using reference equations derived from Caucasian populations. Respirology 2006;11:211-6.
40. Al-Nozha MM, Al-Hazzaa HM, Arafah MR, Al-Khadra A, Al-Mazrou YY, et al. Prevalence of physical activity and inactivity among Saudis aged 30-70 years: A population-based cross-sectional study. Saudi Med J 2007;28:559-68.
41. Adamopoulos S, Parissis J, Karatzas D, Kroupis C, Georgiadis M, Karavolias G, et al. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. J Am Coll Cardiol 2002;39:653-63.
42. Watters LC, King TE, Schwarz MI, Waldron JA, Stanford RE, Cherniack RM. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986;133:97-103.
43. King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: Scoring system and survival model. Am J Respir Crit Care Med 2001;164:1171-81.
44. Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG, et al Idiopathic pulmonary fibrosis: A composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003;167:962-9.